Primary hyperoxaluria: Long‐term outcomes of isolated kidney versus simultaneous liver/kidney transplant
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12315 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Nawras W Habash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Liver Transplantation, Hyperoxaluria, Primary, Graft Rejection. Die Arbeit nennt 37 Literaturangaben. Gefördert von: 2022 Mayo Clinic Small Grant Award. This award is fully supported financially by the T. Denny Sanford Pediatric Collaborative Research Fund between Mayo Clinic….
Abstract (Originalsprache)
Objectives
To compare long‐term transplant outcomes (organ rejection and retransplant) of simultaneous liver/kidney transplant (SLK) versus isolated kidney transplant (IK) for patients with primary hyperoxaluria (PH).
Methods
The Rare Kidney Stone Consortium PH registry was queried to identify patients with PH who underwent SLK or IK from 1999 to 2021. Patient characteristics and long‐term transplant outcomes were abstracted and analyzed. Statistical comparisons were performed with Kaplan–Meier plots and Cox proportional hazards models.
Results
We identified 250 patients with PH, of whom 35 received care at Mayo Clinic and underwent SLK or IK. Patients who underwent SLK as their index transplant had lower odds of kidney rejection than did those who underwent IK (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.08–0.99; p = .048). The immunoprotective effect of concomitant liver and kidney transplant appeared to enhance outcomes for patients with PH. Additionally, the odds of retransplant were significantly lower for patients who underwent SLK as their index transplant than for those who underwent IK (HR, 0.08; 95% CI, 0.02–0.42; p = .003). Of five patients who underwent IK and had maintained graft function for at least 5 years after transplant, three (60%) had documented vitamin B 6 responsiveness.
Conclusions
Patients with PH who underwent SLK had a lower risk of kidney rejection and retransplant than those who underwent IK. Accurate genetic assessment for vitamin B 6 responsiveness may optimize IK allocation. Novel therapeutics, such as lumasiran, have been introduced as promising agents for the management of PH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Pediatric Nephrology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Sara Hassan
Förderung
- 2022 Mayo Clinic Small Grant Award. This award is fully supported financially by the T. Denny Sanford Pediatric Collaborative Research Fund between Mayo Clinic…
Zitieren
APA
Habash, N. W., Jaoudeh, R. A. R. A., Hentz, R. C., Sas, D. J., Ibrahim, S. H., & Hassan, S. (2024). Primary hyperoxaluria: Long‐term outcomes of isolated kidney versus simultaneous liver/kidney transplant. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12315
Vancouver
Habash NW, Jaoudeh RARA, Hentz RC, Sas DJ, Ibrahim SH, Hassan S. Primary hyperoxaluria: Long‐term outcomes of isolated kidney versus simultaneous liver/kidney transplant. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12315
BibTeX
@article{Habash2024,
author = {Habash, Nawras W and Jaoudeh, Rasha A R A and Hentz, Roland C and Sas, David J and Ibrahim, Samar H and Hassan, Sara},
title = {Primary hyperoxaluria: Long‐term outcomes of isolated kidney versus simultaneous liver/kidney transplant},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12315}
}
EUVIMED